Gastrointestinal Cancer | Specialty

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

Dr. Das on the Results of a Clinical Score Analysis in Patients With NETs

January 15th 2021

Satya Das, MD, MSCI, discusses the results of a clinical score analysis in patients with neuroendocrine tumors.

Dr. Strickler on the Rationale for the MOUNTAINEER-02 Trial in HER2+ Gastric/GEJ Cancer

January 15th 2021

John H. Strickler, MD, discusses the rationale for the phase 2/3 MOUNTAINEER-02 trial in HER2-positive gastric/gastroesophageal junction cancer.

Adjuvant S-1/Docetaxel Combo Shows Survival Improvement in Stage III Gastric Cancer

January 15th 2021

January 15, 2021 - Combination treatment with adjuvant S-1 and docetaxel led to an estimated 29% reduction in the risk of relapse compared with S-1 alone in patients with stage III gastric cancer.

FDA Approves Trastuzumab Deruxtecan for HER2+ Metastatic Gastric/GEJ Cancer

January 15th 2021

January 15, 2021- The FDA has approved fam-trastuzumab deruxtecan-nxki for the treatment of adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma who have received a previous trastuzumab-based regimen.

Liposomal Irinotecan Plus 5-FU Shows Real-World OS Benefit in Metastatic PDAC

January 15th 2021

January 15, 2021 - One-year overall survival was found increased the longer that patients with metastatic pancreatic ductal adenocarcinoma remained on treatment with liposomal irinotecan plus 5-fluorouracil/leucovorin.

Pembrolizumab Triplet Appears Effective in HER2+ Advanced Gastric, GEJ Cancer Regardless of PD-L1 Status

January 15th 2021

January 15, 2021 - Pembrolizumab with trastuzumab and the combination of cisplatin and capecitabine appeared effective in treating HER2-positive advanced gastric and gastroesophageal junction cancer, regardless of a patient’s PD-L1 status.

Nivolumab Improves Quality of Life in Patients with Esophageal/Gastroesophageal Cancer

January 15th 2021

January 15, 2021 - Patients with esophageal/gastroesophageal cancer treated with nivolumab had improved esophageal-specific and general quality of life, although trends were similar in those treated with placebo.

Camrelizumab/Apatinib Shows Promising Activity in Second-Line Esophageal Squamous Cell Carcinoma

January 15th 2021

January 15, 2021 - A novel combination comprised of camrelizumab and apatinib was found to have promising clinical efficacy with an acceptable safety profile when used as a second-line treatment in patients with esophageal squamous cell carcinoma.

Pembrolizumab/Lanreotide Combo Confers Antitumor Activity in GEP-NETs

January 15th 2021

January 15, 2021 - Pembrolizumab plus lanreotide elicited a stable disease rate of 39% in patients with advanced, progressive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), according to findings from the phase 1b/2 PLANET study.

AI-Based Tool May Help Patients Find GI Cancer Clinical Trials

January 15th 2021

January 15, 2021 - A novel artificial intelligence-based search tool made it easier for patients to find and understand cancer clinical trials, while also offering more clarity on how to enroll in them

Invasive Gastrointestinal Stromal Tumors More Common in Men, Initiating in the Small Intestine and Stomach

January 15th 2021

January 15, 2021 - Findings from an analysis determined that stage 4 gastrointestinal stromal tumors were rare and led to hepatic metastases, although overall survival was up to 51% at 5 years.

Pembrolizumab Plus Capecitabine/Bevacizumab Shows Favorable Tolerability in MSS mCRC

January 15th 2021

January 15, 2021 - Pembrolizumab (Keytruda) in combination with capecitabine and bevacizumab (Avastin) was found to show encouraging tolerability when used in patients with microsatellite stable (MSS) metastatic colorectal cancer (mCRC), according to data from a phase 2 trial (NCT03396926) presented during the 2020 Gastrointestinal Cancers Symposium.

Dr. Kelly on the Safety Profile of Adjuvant Nivolumab in Resected Esophageal/GEJ Cancer

January 14th 2021

Ronan J. Kelly, MD, MBA, discusses the safety profile of adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer.

Dr. Sun on the KEYNOTE-062 Design in Advanced Gastric/GEJ Cancer

January 14th 2021

Weijing Sun, MD, FACP, discusses the design of the KEYNOTE-062 trial in advanced gastric/gastroesophageal junction cancer.

Dr. Berlin on Unmet Needs in Pancreatic Cancer

January 14th 2021

Jordan D. Berlin, MD, discusses unmet needs in pancreatic cancer.

Addition of HIPEC to Cytoreductive Surgery in CRC Peritoneal Carcinomatosis Warrants Further Investigation

January 13th 2021

Prakash Pandalai, MD, discusses the role of HIPEC in CRC peritoneal carcinomatosis and data from the PRODIGE 7 and PROPHYLOCHIP-PRODIGE 15 trials.

Aggressive Treatment Approaches Expected to Move Dial in Metastatic Colon Cancer

January 13th 2021

Michael J. Cavnar, MD, highlights the role of surgery in colon cancer, the role of tumor sidedness in informing surgical decisions, and research efforts that are being done to evaluate the utility of hepatic artery infusion pumps.

Dr. Chalabi on the Role of MSI Testing in CRC

January 13th 2021

Myriam Chalabi, MD, discusses the utility of microsatellite instability (MSI) testing in colorectal cancer,

Dr. Janjigian on the Importance of Routine HER2 Testing in Gastric/GEJ Cancer

January 13th 2021

Yelena Y. Janjigian, MD, discusses the importance of routine HER2 testing in gastric/gastroesophageal cancer.

Adjuvant Oxaliplatin Added to Fluoropyridine Improves Survival in Stage III MSI-High Colon Cancer

January 12th 2021

The addition of adjuvant oxaliplatin to fluoropyridine improves overall survival and disease-free survival compared with fluoropyridine alone in patients with stage III colon cancer with microsatellite instability.